MetaCap

Tevogen Inc. (TVGN)

NASDAQ: TVGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

5.90-0.40 (-6.35%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TVGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$405.20M
EPS (TTM)
-$7.01
52-week range
3.64 – 24.90
Day range
5.72 – 6.35
Volume / Avg
9.35K / 7.94K
Beta
—

52-week range

$3.64$24.90

TVGN stock today

Shares of Tevogen (TVGN) finished lower on Nov 20 at $5.90, a drop of 6.35% or $0.40 per share, versus the S&P 500's 3.70% decline. Shares are 76.3% below their 52-week high of $24.90, set on Nov 26, 2025 and 62.3% above the 52-week low of $3.64, near the bottom of the past year's range. TVGN is down 64.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 73.8%.

Tevogen has posted a net loss over the last twelve months (EPS of -$7.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tevogen

Company profile

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Ryan H. Saadi M.D., M.P.H.
Headquarters
Warren, NJ
Employees
18
IPO year
2022

Financial highlights

Full financials

Tevogen reported a net loss of $26.3 million, compared with a loss of $13.7 million a year earlier. Diluted earnings per share came in at -$8.08.

Tevogen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-26.28M$-13.73M$-60.48M$4.41M
EPS (diluted)$-8.08$-3.50$-2.44—

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-1.76 vs —

TVGN news

All TVGN news

Tevogen peers

Health Care sector
TVGN peer companies
CompanyPrice% ChgMarket capCompare
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs TVGN
CADLCandel Therapeutics Inc.5.04-1.75%$395.37Mvs TVGN
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs TVGN
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs TVGN
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs TVGN
ALECAlector Inc.2.34+1.52%$347.63Mvs TVGN
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs TVGN
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs TVGN

Indexes, lists and sector

Tevogen stock FAQ

What is Tevogen's stock price today?

TVGN last traded at $5.90 as of Nov 20, 4:00 PM EST, down 6.35% on the day. Prices are delayed at least 15 minutes.

Does Tevogen pay a dividend?

No. Tevogen does not currently pay a regular cash dividend.

Who is Tevogen's CEO?

Dr. Ryan H. Saadi M.D., M.P.H. is the chief executive officer of Tevogen Inc., which has about 18 employees.

Has TVGN ever split its stock?

Yes. The most recent TVGN stock split was a 1-for-50 split on Mar 6, 2026.

What is the TVGN 52-week high?

The 52-week high for TVGN is $24.90 and the 52-week low is $3.64. The stock is currently 76.3% below its high.

Compare TVGN